Page 6 - Pascal Deschatelets News Today

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) insider Pascal Deschatelets sold 12,000 shares of the business’s stock in a transaction that occurred on Thursday, June 8th. The shares were sold at an average price of $91.35, for a total value of $1,096,200.00. Following the completion of the sale, the insider now owns 1,040,313 shares of […]

Teacher Retirement System of Texas reduced its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) by 3.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,002 shares of the company’s stock after selling 860 shares during the period. […]

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) CFO Timothy Eugene Sullivan sold 69,779 shares of the firm’s stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $88.80, for a total transaction of $6,196,375.20. Following the sale, the chief financial officer now owns 77,713 shares in […]

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) have been assigned an average rating of “Moderate Buy” from the fourteen brokerages that are presently covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating […]

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) has been assigned a consensus recommendation of “Moderate Buy” from the fourteen research firms that are presently covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the […]

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) was the target of a large growth in short interest in May. As of May 15th, there was short interest totalling 11,000,000 shares, a growth of 7.0% from the April 30th total of 10,280,000 shares. Based on an average daily trading volume, of 1,980,000 shares, the short-interest ratio […]

Daré Bioscience (NASDAQ:DARE – Get Rating) and Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk. Analyst Recommendations This is a breakdown of recent recommendations and […]

Mirae Asset Global Investments Co. Ltd. raised its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) by 5.3% during the 4th quarter, HoldingsChannel reports. The firm owned 45,179 shares of the company’s stock after acquiring an additional 2,291 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Apellis Pharmaceuticals were worth […]

Tekla Capital Management LLC lowered its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) by 75.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 66,426 shares of the company’s stock after selling 199,650 shares during the period. Tekla Capital Management LLC […]

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) CEO Cedric Francois sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 16th. The stock was sold at an average price of $85.66, for a total value of $2,569,800.00. Following the sale, the chief executive officer now owns 274,655 shares of the […]